OREXO

One of the most important objectives has been to broaden the product portfolio to capitalize the US commercial organization. In 2019, a collaboration was initiated with GAIA, a world leader in the development of digital therapeutics, and in 2020, Orexo's product portfolio grew with three digital therapies... Orexo develops improved pharmaceuticals and digital therapies addressing unmet needs within the growing space of mental illness and substance use disorders. The products are commercialized by Orexo in the US or via partners worldwide. The main market today is the American market for buprenorphine/naloxone products, where Orexo commercializes its lead product ZUBSOLV® for the treatment of opioid use disorder. Total net sales for 2022 amounted to SEK 624 million and the number of employees was 126... Orexo's business model is integrated and includes the entire value chain, from the innovation phase to product access and commercialization. Cross-functional teams bring together..

Also known as: Orexo AB, Orexo AB (publ.), Orexo US, Orexo US Inc.

Registration numbers: 556500-0600 (W)

VAT numbers: SE556500-060001

Primary location: Morristown United States